You have to understand that I think gene patents per se are b*llsh*t. And I think that the Court of Appeals has just disagreed with me. If you can patent a gene itself or a gene sequence itself, the stuff Incyte has gains some value, whether or not they have taught what it is good for.
In their investor communications, Incyte hasn't referred to their gene patents for years; their management doesn't act like they think much value should be attached to them. So I'm not beating a drum here, I'm just saying that if a pure gene patent is worth something, that's a place to look.
Nice, but not terribly meaningful to owners. The main issue for us is the ongoing legal expenses. There figures to be another go-round at this level in the system, and then a SCOTUS appeal. Another 2 years of financial drain. Well, at least it's moving.